Gilead Sciences, Inc. (GILD) operating KPIs
GILDNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026Score 11/30105% above fair value
$170.68+5.07 (+3.06%)
Close on Oct 30, 2026Market cap $211.64BP/E –Yield 1.85%
Gilead Sciences accrued rebates and chargebacks liability (Balance Sheet, $M) ($M)
Form 10-Q / 10-K Accrued Liabilities & Critical Accounting Estimates
Latest, Q2 2026
4,233
Period ended Jun 30, 2026
Change on a year earlier
+0.4%
4,215 in Q2 2025
History
16 quarters
Since Q4 2021
Sources
15
Documents cited below
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Accrued rebates and chargebacks liability (Balance Sheet, $M) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q2 2026 | Jun 30, 2026 | 4,233 | +0.4% | Form 10-Q (filed 2026-08-06) ↗ |
| Q1 2026 | Mar 31, 2026 | 4,118 | -1.6% | Form 10-Q (filed 2026-05-07) ↗ |
| Q4 2025 | Dec 31, 2025 | 4,337 | +11.4% | Form 10-Q (filed 2026-08-06) ↗ |
| Q3 2025 | Sep 30, 2025 | 4,931 | +19.9% | Form 10-Q (filed 2025-11-07) ↗ |
| Q2 2025 | Jun 30, 2025 | 4,215 | +7.4% | Form 10-Q (filed 2025-08-07) ↗ |
| Q1 2025 | Mar 31, 2025 | 4,185 | -1.8% | Form 10-Q (filed 2025-05-07) ↗ |
| Q4 2024 | Dec 31, 2024 | 3,892 | +2.4% | Form 10-K (filed 2026-02-24) ↗ |
| Q3 2024 | Sep 30, 2024 | 4,113 | +10.7% | Form 10-Q (filed 2024-11-12) ↗ |
| Q2 2024 | Jun 30, 2024 | 3,923 | +12.3% | Form 10-Q (filed 2024-08-08) ↗ |
| Q1 2024 | Mar 31, 2024 | 4,263 | +22.6% | Form 10-Q (filed 2024-05-08) ↗ |
| Q4 2023 | Dec 31, 2023 | 3,802 | +9.3% | Form 10-K (filed 2025-02-28) ↗ |
| Q3 2023 | Sep 30, 2023 | 3,714 | – | Form 10-Q (filed 2023-11-07) ↗ |
| Q2 2023 | Jun 30, 2023 | 3,494 | – | Form 10-Q (filed 2023-08-04) ↗ |
| Q1 2023 | Mar 31, 2023 | 3,477 | – | Form 10-Q (filed 2023-05-03) ↗ |
| Q4 2022 | Dec 31, 2022 | 3,479 | +7.2% | Form 10-K (filed 2024-02-23) ↗ |
| Q4 2021 | Dec 31, 2021 | 3,244 | – | Form 10-K (filed 2023-02-22) ↗ |
Breakdown
What makes up accrued rebates and chargebacks liability (balance sheet, $m)
- Total gross-to-net (GTN) deductions ($M)–
- Gross-to-net deductions as % of gross product sales (%)–
- Rebates & chargebacks rollforward — Beginning balance ($M)–
- Rebates & chargebacks rollforward — Total provision (decrease to product sales, $M)–
- Rebates & chargebacks rollforward — Total payments ($M)–
- Rebates & chargebacks rollforward — Ending balance ($M)–
Cite this data
StockData. (2026). Gilead Sciences Accrued rebates and chargebacks liability (Balance Sheet, $M) ($M), quarterly Q4 2021–Q2 2026 [Data set]. Compiled from Gilead Sciences SEC filings and investor materials. https://stockdatahq.com/stocks/gild/kpis/gtn_rebates_liab
See every metric in the Gilead Sciences KPI table. Data updated Oct 29, 2026.